Economic impact of using inhaled corticosteroids without prior exacerbation among elderly patients with chronic obstructive pulmonary disorder

Journal of Medical Economics

Volumn 14, Issue 4, 2011, Pages 458-462

  Chen, S ^a   Plauschinat, C A ^b   Wu, N ^a   Fraser, K ^a   Boulanger, L ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chronic obstructive pulmonary disease; Exacerbation; Healthcare costs; Inhaled corticosteroids

Indexed keywords

CORTICOSTEROID;

AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CYSTIC FIBROSIS; DISEASE EXACERBATION; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGE FACTORS; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEX FACTORS; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 79960146020     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.588981     Document Type: Article

References (21)

1. American Lung Association. Chronic Obstructive Pulmonary Disease. [cited 2009 April 3]; Available from: www.lungusa.org
2. National Heart Lung and Blood Institute, Morbidity and Mortality: 2007 Chartbook on Cardiovascular, Lung and Blood Diseases. 2007 [cited 2009 April 3]; Available from: www.nhlbi.nih.gov
3. American Association of Respiratory Care (AARC). COPD Resources. [cited 2009 April 3]; Available from: www.aarc.org
4. Chronic Obstructive Pulmonary Disease (COPD). Department of Health and Human Services. Centers for Disease Control and Prevention. [cited 2009 April 3]; Available from: www.cdc.gov
5. Institute for Clinical Systems Improvement (ICSI). Chronic obstructive pulmonary disease. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI). 2007 [cited 2009 April 3]; Available from: www.clinicaltrials.gov
6. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2008). [cited 2009 April 3]; Available from: www.goldcopd.gov
7. National Institute for Health and Clinical Excellence (NICE). Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. 2004 [cited 2009 April 3]; Available from: www.nice.org.uk
8. Braman SS. Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines. Chest 2006;129(1 Suppl):104-15S
9. Qaseem A, Snow V, Shekelle P, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2007;147:633-8 (Pubitemid 351664484)
10. Finnish Medical Society Duodecim. Chronic obstructive pulmonary disease (COPD). In: EBM Guidelines. Evidence-Based Medicine. [cited 2009 April 3]; Available from: www.clinicaltrials.gov
11. Asche CV, Brixner DI, Sonoscenti CS, et al. Assessment of physician prescribing for primary care patients with chronic obstructive pulmonary disease (COPD) in a national electronic medical record (EMR) research database. Chest 2006;130:175S
12. Lucas AEM, Smeenk FW, Smeele IJ, et al. Overtreatment with inhaled corticosteroids and diagnostic problems in primary care patients, an exploratory study. Fam Pract 2008;25:86-91 (Pubitemid 351753538)
13. Wu N, Plauschinat C, Chen S, et al. Inhaled corticosteroid use and prior exacerbations among patients with chronic obstructive pulmonary disorder. Am J Respir Crit Care Med 2010;181:A4485
14. Charlson ME, Charlson RE, Peterson JC, et al. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008;61:1234-40
15. Bureau of Labor Statistics: Consumer Price Index. January 2008 [cited 2009 April 3]; Available from: www.bls.gov
16. Afifi AA, Kotlerman JB, Ettner SL, et al. Methods for improving regression analysis for skewed continuous or counted responses. Annu Rev Public Health 2007;28:95-111 (Pubitemid 46833335)
17. McCullagh P, Nelder JA. Generalized Linear Models, 2nd edn. London: Chapman and Hall, 1989
18. Van Schayck CP, Van Grunsven PM, Dekhuijzen PNR. Do patients with COPD benefit from treatment with inhaled corticosteroids? Eur Respir J 1996; 9:1969-72 (Pubitemid 26333528)
19. Nannini LJ, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and longacting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews (Online) 2007(4):CD006829
20. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease. Arch Intern Med 2009;169:219-29
21. Chanez P, Vignola AM, OShaugnessy T, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997; 155:1529-34 (Pubitemid 27216654)